CP

Caligan Partners Portfolio holdings

AUM $721M
1-Year Est. Return 355.96%
This Quarter Est. Return
1 Year Est. Return
+355.96%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$721M
AUM Growth
+$206M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
21
New
Increased
Reduced
Closed

Top Buys

1
+$38.7M
2
+$28.6M
3
+$20M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$17.8M
5
AVTX icon
Avalo Therapeutics
AVTX
+$10.6M

Top Sells

1
+$136M
2
+$41.4M
3
+$18.9M
4
YMAB
Y-mAbs Therapeutics
YMAB
+$10.6M
5
RZLT icon
Rezolute
RZLT
+$6.88M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$2.93B
$185M 24.18%
8,118,892
ABVX
2
Abivax
ABVX
$8.54B
$123M 16.15%
1,451,924
-222,476
MLYS icon
3
Mineralys Therapeutics
MLYS
$3.08B
$105M 13.77%
2,772,654
+755,302
EXEL icon
4
Exelixis
EXEL
$11.9B
$63M 8.25%
1,525,730
RVMD icon
5
Revolution Medicines
RVMD
$15.2B
$49.7M 6.51%
1,064,249
+427,414
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.59B
$45.4M 5.95%
1,131,205
+59,947
ADMA icon
7
ADMA Biologics
ADMA
$4.79B
$38.7M 5.06%
+2,636,609
EOLS icon
8
Evolus
EOLS
$441M
$25.4M 3.33%
4,138,943
+796,973
MRUS icon
9
Merus
MRUS
$7.29B
$20.4M 2.68%
216,954
-440,045
XENE icon
10
Xenon Pharmaceuticals
XENE
$3.44B
$17.8M 2.34%
+444,565
ANIK icon
11
Anika Therapeutics
ANIK
$137M
$13.5M 1.77%
1,435,130
AVTX icon
12
Avalo Therapeutics
AVTX
$328M
$10.6M 1.39%
+833,333
TYRA icon
13
Tyra Biosciences
TYRA
$1.16B
$9.75M 1.28%
696,825
+506,875
INBX icon
14
Inhibrx
INBX
$1.25B
$7.96M 1.04%
+236,383
VRCA icon
15
Verrica Pharmaceuticals
VRCA
$78.1M
$3.98M 0.52%
923,910
-2
AURA icon
16
Aura Biosciences
AURA
$408M
$1.4M 0.18%
227,174
+27,174
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$1.69B
– –
-638,908
RZLT icon
18
Rezolute
RZLT
$889M
– –
-1,543,014
SLS icon
19
SELLAS Life Sciences
SLS
$252M
– –
0
VRNA
20
DELISTED
Verona Pharma
VRNA
– –
-1,436,878
YMAB
21
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-2,342,609